Skip to main content
AmigoFish

STIFEL 2026: Cullinan Therapeutics' CEO Nadim Ahmed gives an overview of the progress of the company's T-cell engagers in autoimmune and oncology (and more)

From BiotechTV - News · · 11 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

He goes over a partner's BCMA data that was just presented this weekend at ACR in lupus, and previews a key CD19 update that Cullinan will be providing investors in December. Plus, he comments on zipalertinib, which is in front of FDA now in two lines of therapy.

Back to BiotechTV - News · Report a problem